These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37385233)

  • 21. Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.
    Fukuoka H; Tachibana K; Shinoda Y; Minamisaka T; Inui H; Ueno K; Inoue S; Mine K; Ueda K; Hoshida S
    BMC Cardiovasc Disord; 2020 Oct; 20(1):467. PubMed ID: 33121430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study.
    Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
    Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute and acute-on-chronic kidney injury of patients with decompensated heart failure: impact on outcomes.
    Zhou Q; Zhao C; Xie D; Xu D; Bin J; Chen P; Liang M; Zhang X; Hou F
    BMC Nephrol; 2012 Jul; 13():51. PubMed ID: 22747708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction　- Prospective Randomized Controlled Study.
    Tamaki S; Sato Y; Yamada T; Morita T; Furukawa Y; Iwasaki Y; Kawasaki M; Kikuchi A; Kondo T; Ozaki T; Seo M; Ikeda I; Fukuhara E; Abe M; Nakamura J; Fukunami M
    Circ J; 2017 Apr; 81(5):740-747. PubMed ID: 28202885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure.
    Morita Y; Endo A; Kagawa Y; Yamaguchi K; Sato H; Ouchi T; Watanabe N; Tanabe K
    Heart Vessels; 2021 Jun; 36(6):836-843. PubMed ID: 33527152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
    Ng TMH; Grazette LP; Fong MW; Yoon AJ; Lou M; Kuo A; Upadhyay RY; Han EE; Mehra A; Elkayam U
    ESC Heart Fail; 2020 Aug; 7(4):1927-1934. PubMed ID: 32543020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum lactate level may predict the development of acute kidney injury in acute decompensated heart failure.
    Kahyaoglu M; Karaduman A; Geçmen Ç; Candan Ö; Güner A; Cakmak EO; Bayam E; Yılmaz Y; Çelik M; Izgi IA; Kirma C
    Turk Kardiyol Dern Ars; 2020 Oct; 48(7):683-689. PubMed ID: 33034575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
    Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
    Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of Tolvaptan Compared With Increased Dose of Furosemide in Heart Failure Patients With Chronic Kidney Disease Under Furosemide Treatment.
    Tanaka T; Minatoguchi S; Yamada Y; Kanamori H; Kawasaki M; Nishigaki K; Minatoguchi S
    Circ Rep; 2018 Dec; 1(1):35-41. PubMed ID: 33693073
    [No Abstract]   [Full Text] [Related]  

  • 33. Mechanisms of Diuresis for Acute Decompensated Heart Failure by Tolvaptan.
    Nomoto H; Satoh Y; Kamiyama M; Yabe K; Masumura M; Sakakibara A; Yamashita S; Suzuki M; Sugiyama T; Oumi T; Ohno M; Takahashi Y; Isobe M
    Int Heart J; 2017 Aug; 58(4):593-600. PubMed ID: 28701677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolvaptan, Is It a Trump to Worsening Renal Function?
    Momomura SI
    Circ J; 2017 Apr; 81(5):642-644. PubMed ID: 28420818
    [No Abstract]   [Full Text] [Related]  

  • 35. Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.
    Nagayama I; Masuda T; Nakagawa S; Murakami T; Ohara K; Matsuoka R; Kobayashi T; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Intern Med; 2019 Jun; 58(11):1587-1591. PubMed ID: 30713322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal ultrasonography predicts worsening renal function in patients with heart failure under tolvaptan administration.
    Tanaka N; Furukawa Y; Maeda T; Ishihara H; Dan K; Teramura M; Ichihashi K; Takase T; Takahashi Y; Tsuzura D; Shinoda A; Fujii M; Okada H; Itabashi F; Teramoto T
    ESC Heart Fail; 2024 Aug; 11(4):1911-1918. PubMed ID: 38468548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.
    Takimura H; Kurozumi A; Taniguchi R; Tsuzuki I; Tajima E; Yamaguchi Y; Kawano M; Takimura Y; Nishio S; Nakano M; Tsukahara R
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):185-196. PubMed ID: 36739357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    Int J Cardiol; 2016 Oct; 221():188-93. PubMed ID: 27404673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery.
    Yamada M; Nishi H; Sekiya N; Horikawa K; Takahashi T; Sawa Y
    Surg Today; 2017 Apr; 47(4):498-505. PubMed ID: 27553014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.